Pre-trial implementation study for ketamine in sickle cell disease

NIH RePORTER · NIH · U24 · $305,888 · view on reporter.nih.gov ↗

Abstract

Specific Aim 1: Assess healthcare stakeholders' perceptions of barriers to and facilitators for a RCT of early administration of sub-anesthetic ketamine infusion as a pain adjunct for VOEs using the Consolidated Framework for Implementation Research (CFRIR) and Proctor's taxonomy for implementation outcomes. To achieve this, we will: 1A: Conduct a cross-sectional survey study of healthcare professionals within EPPIC-Net who provide care for people with SCD and/or provide guidance for administration of ketamine within their hospital system (i.e., specialties including hematology, emergency medicine, anesthesiology, and hospitalist medicine) to assess barriers to and facilitators for the proposed RCT 1B: Conduct semi-structured interviews of 15-20 healthcare professionals to assess barriers to and facilitators for the proposed RCT.

Key facts

NIH application ID
10526631
Project number
3U24NS114416-01S2
Recipient
DUKE UNIVERSITY
Principal Investigator
Francis J. Keefe
Activity code
U24
Funding institute
NIH
Fiscal year
2022
Award amount
$305,888
Award type
3
Project period
2022-09-15 → 2023-08-14